SCHEMBL23883291

SCHEMBL23883291

CC(C)C[C@H](NC(=O)OC1CCCCC1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.53
ALDH1A1 P00352 2/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
KMT2A Q03164 1/20 0.50
FOLH1 Q04609 6/20 0.47
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
MAPT P10636 1/20 0.44
LAP3 P28838 3/20 0.43
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
ITGB3 P05106 1/20 0.41
ITGAV P06756 1/20 0.41
EDNRA P25101 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23883294 1.00 EPHX1 (0.53) EPHX1ALDH1A1MEN1LMNAKMT2A
SCHEMBL28969225 0.87 SMN1; SMN2 (0.54) EPHX1FOLH1HDAC4HDAC1LAP3
SCHEMBL28969227 0.87 SMN1; SMN2 (0.54) EPHX1FOLH1HDAC4HDAC1LAP3
SCHEMBL23883316 0.85 ALDH1A1 (0.46) ALDH1A1MEN1LMNAKMT2AFOLH1
SCHEMBL21457960 0.85 ALDH1A1 (0.46) ALDH1A1MEN1LMNAKMT2AFOLH1
SCHEMBL23883313 0.85 ALDH1A1 (0.46) ALDH1A1MEN1LMNAKMT2AFOLH1
SCHEMBL3843959 0.85 ALDH1A1 (0.46) ALDH1A1MEN1LMNAKMT2AFOLH1
SCHEMBL23883265 0.84 ALDH1A1 (0.45) ALDH1A1MEN1LMNAKMT2AFOLH1
SCHEMBL23883293 0.84 ALDH1A1 (0.45) EPHX1ALDH1A1MEN1LMNAKMT2A
SCHEMBL23883296 0.84 ALDH1A1 (0.45) EPHX1ALDH1A1MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115667215-B Broad-spectrum antiviral medicine for resisting coronavirus 堪萨斯州立大学研究基金会 2026-05-19 CN disclosed
US-12583820-B2 Broad spectrum antivirals against coronavirus KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2026-03-24 US disclosed
US-20230150933-A1 BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS UNIVERSITY OF IOWA RESEARCH FOUNDATION 2023-05-18 US disclosed
EP-4126816-A1 BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS Kansas State University Research Foundation (US) 2023-02-08 EP disclosed
CN-115667215-A Broad-spectrum antiviral medicine for resisting coronavirus 堪萨斯州立大学研究基金会 2023-01-31 CN disclosed
WO-2021202460-A1 BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2021-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583820-B2 Broad spectrum antivirals against coronavirus SARS1, NSUN2, ZC3HAV1 EPHX1 3179/4885ALDH1A1 1431/4885MEN1 4769/4885
US-20230150933-A1 BROAD SPECTRUM ANTIVIRALS AGAINST CORONAVIRUS SARS1, ZC3HAV1, POLL EPHX1 3004/4885ALDH1A1 2499/4885MEN1 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.